It has been noted that MCPyV-negative MCC shares a similar mutational profile to that of small cell lung cancer (SCLC) [70], which demonstrates a high expression of DNA repair proteins, particularly PARP1 [71], thus prompting investigation by Ferrarotto in 2018 into the use of PARP1 as a therapeutic target for MCC. This evidence concerns the gene PARP1 and small cell lung carcinoma.